title: Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies.
abstract: The use of opioids for treating neuropathic pain is controversial, and some studies have indicated that neuropathic pain may be relatively insensitive to typical mu-opioid analgesics such as morphine. However, it is becoming clear that different opioids produce analgesia by affecting different pain pathways. We present two cases of neuropathic pain and two cases of nociceptive pain with a significant neuropathic component that were treated with transdermal buprenorphine. In each case, sufficient pain relief was obtained and no problems were encountered in switching from prior analgesic therapy with larger doses of other opioids.
authors.affiliation: *Pain Clinic, General Hospital Klagenfurt, Klagenfurt, Austria; and †University of Erlangen Pain Clinic, Erlangen, Germany.
authors.forename: Rudolf
authors.initials: R
authors.lastname: Likar
authors.forename: Reinhard
authors.initials: R
authors.lastname: Sittl
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000701:Analgesics, Opioid / Q000008:administration & dosage*; D002047:Buprenorphine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy*
chemical_list: D000701:Analgesics, Opioid; D002047:Buprenorphine
references.citation: McQuay HJ. Neuropathic pain: evidence matters. Eur J Pain 2002;6(Suppl A):11–8.
references.citation: Foley KM. Opioids and neuropathic pain. N Engl J Med 2003;348:1279–81.
references.citation: Payne R. Neuropathic pain syndromes with special reference to causalgia and reflex sympathetic dystrophy. Clin J Pain 1986;2:59–73.
references.citation: Arnér S, Myerson B. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988;33:11–23.
references.citation: Rowbotham M. The debate over neuropathic pain. In: Kalso E, McQuay H, Wiesenfeld-Hallin Z, eds. Opioids sensitivity of chronic noncancer pain. Seattle: IASP Press, 1988:207–318.
references.citation: Dellemijn PLI, Vanneste JAL. Randomised double-blind active-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 1997;349:753–8.
references.citation: Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998;50:1842–6.
references.citation: Sindrup SH, Andersen G, Madsen C, et al. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999;83:85–90.
references.citation: Rowbotham MC, Twilling L, Davies PS, et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003;348:1223–32.
references.citation: Mao J, Price DD, Mayer DJ. Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 1995;61:353–64.
references.citation: Lewis JW, Husbands SM. The orvinols and related opioids: high affinity ligands with diverse efficacy profiles. Curr Pharm Des 2004;10:717–32.
references.citation: McCormack K. Signal transduction in neuropathic pain, with special emphasis on the analgesic role of opioids. Part II: Moving basic science towards a new pharmacotherapy. Pain Reviews 1999;6:99–131.
references.citation: Kouya PF, Hao J-X, Xu X-J. Buprenorphine alleviates neuropathic pain-like behaviors in rats after spinal cord and peripheral nerve injury. Eur J Pharmacol 2002;450:49–53.
references.citation: Benedetti F, Vighetti S, Amanzio M, et al. Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain 1998;74:205–11.
references.citation: Omote K, Ohmori H, Kawamata M, et al. Intrathecal buprenorphine in the treatment of phantom limb pain. Anesth Analg 1995;80:1030–2.
references.citation: Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Therapeutics 2003;25:150–68.
references.citation: Spendel MC, Deinsberger R, Lanner G. Operative treatment of trigeminal neuralgia. Stereotact Funct Neurosurg 1997;68(1–4 Pt 1):187–9.
references.citation: Spacek A, Böhm D, Kress HG. Ganglionic local opioid analgesia for refractory trigeminal neuralgia. Lancet 1997;349(9064):1521.
references.citation: Martin WR, Eades CG, Thompson JA, et al. The effects of morphine and morphine-like drugs in the non-dependent and morphine-dependent spinal dog. J Pharmacol Exp Ther 1976;197:517–32.
references.citation: Leander JD. Buprenorphine is a potent κ-opioid receptor antagonist in pigeons and in mice. Eur J Pharmacol 1988;151:457–61.
references.citation: Bryant RM, Olley JE, Tyers MB. Antinociceptive action of morphine and buprenorphine given intrathecally in the conscious rat. Br J Phamacol 1983;78:659–63.
references.citation: Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. The pharmacological basis of therapeutics. New York: Pergammon Press, 1990:485–521.
references.citation: Budd K. High dose buprenorphine for postoperative analgesia. Anaesthesia 1981;36:900–3.
references.citation: Yaksh TL. Spinal opiate analgesia: characteristics and principles of action. Pain 1981;11:293–346.
references.citation: Parenti M, Tirone F, Giagnoni G, et al. Pertussis toxin inhibits the antinociceptive action of morphine in the rat. Eur J Pharmacol 1986;124:357–9.
references.citation: Sanchez-Blazquez P, Garzon J. Pertussis toxin differentially reduces the efficacy of opioids to produce supraspinal analgesia in the mouse. Eur J Pharmacol 1988;152:357–61.
references.citation: Hoehn K, Reid A, Sawynok J. Pertussis toxin inhibits antinociception produced by intrathecal injection of morphine, adrenaline, and baclofen. Eur J Pharmacol 1988;146:65–72.
references.citation: Rothman RB, Ni Q, Xu H. Buprenorphine: a review of the binding literature. In: Cowan A, Lewis AJ, eds. Buprenorphine: combating drug abuse with a unique opioid. New York: Wiley-Liss, 1995:19–29.
references.citation: Ocaña M, Del Pozo E, Barrios M, Baeyens JM. Subgroups among μ-opioid receptor agonists distinguished by ATP-sensitive K+ channel-acting drugs. Br J Pharmacol 1995;114:1296–302.
references.citation: McLaughlin CR, Dewey RL. A comparison of the antinociceptive effects of opioid agonists in neonatal and adult rats in phasic and tonic nociceptive tests. Pharmacol Biochem Behav 1994;49:1017–23.
references.citation: Staats PS, Johnson RE. New perspectives on the pharmacology of opioids and their use in chronic pain. Prog Anaesthesiol 2002;16:235–49.
references.citation: Budd K. Experience with partial agonist in the treatment of cancer pain. R Soc Med Services Int Congress Symposium 1990;146:51–4.